Editorial introductions

Section Editor(s): Duerr, Ann; Arthos, James

Current Opinion in HIV & AIDS: March 2012 - Volume 7 - Issue 2 - p v
doi: 10.1097/COH.0b013e3283510911
Editorial introductions

Current Opinion in HIV and AIDS was launched in 2006. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The fields of HIV and AIDS are divided into nine sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Section Editors for this issue.

Back to Top | Article Outline


Ann Duerr

Throughout her career, Dr Duerr has been interested in public health issues of resource-limited settings, with a special emphasis on HIV and women's health. She trained in laboratory science, medicine, and infectious disease epidemiology - she received a BSc degree from McGill University, Canada, a PhD from Massachusetts Institute of Technology, USA, an MD from Harvard University, USA, and an MPH from Johns Hopkins University, USA. For over 20 years, her research has been focused on HIV. Her initial epidemiologic research focused on parameters associated with HIV transmission from women to infants in Rwanda and on fully characterizing the clinical course of HIV infections in US women. More recently, her work has been focused on prevention – specifically, on an intervention among African women to prevent mother-to-child HIV transmission via breastfeeding; as well as on trials of prophylactic HIV vaccines, as Director for Scientific Affairs of the HIV Vaccine Trials Network (HVTN). The HVTN is an international partnership of researchers with 25 sites on four continents conducting studies of the safety, immunogenicity, and efficacy studies of HIV vaccine candidates. She also conducts clinical studies and research in non-human primates investigating ways to increase vaccine-induced immunity at mucosal surfaces, the site of infection for most pathogens and is currently working on studies of antiretroviral treatment to prevent onward HIV transmission in Peru and South Africa.

Back to Top | Article Outline

James Arthos

Dr Arthos obtained a PhD from the University of Pennsylvania, USA and subsequently worked as a Post-Doctoral Fellow in the Department of Microbiology and Immunology at The Stanford University School of Medicine, USA. He is currently a Staff Scientist in the Laboratory of Immunoregulation in the National Institute of Allergy and Infectious Diseases on the NIH campus in Bethesda, Maryland, USA. He began working on the HIV-1 envelope protein and its interaction with cell surface receptors under the direction of Raymond Sweet and Marty Rosenberg who headed up a team of researchers in the Department of Molecular Genetics at SmithKline, and was involved in the initial design, development and characterization of recombinant forms of sCD4 and gp120. He has continued to focus on the interaction between gp120 and cellular receptors and has incorporated into those studies interactions between gp120 various receptors including CCR5, DC-SIGN, and more recently integrin α4β7.

© 2012 Lippincott Williams & Wilkins, Inc.